Patents by Inventor Marc Rothenberg

Marc Rothenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel therapeutic target and diagnostic marker for asthma and related conditions
    Publication number: 20070212353
    Abstract: CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression.
    Type: Application
    Filed: February 14, 2007
    Publication date: September 13, 2007
    Applicant: Yissum Research Development Company of The Hebrew University of Jerusalem
    Inventors: Francesca Levi-Schaffer, Ido Bachelet, Marc Rothenberg, Ariel Munitz
  • TREATMENT FOR ASTHMA AND ALLERGY
    Publication number: 20070190567
    Abstract: Several genes are upregulated in the lung of asthma or allergy sufferers. Many of the genes up-regulated in asthma are involved in arginine metabolism in the lung. Moreover, a set of 291 signature genes was found that can be used to indicate a patient's predilection for developing asthma or the patient's degree of suffering. Also, a set of 59 signature genes were found that indicate a patient's predilection for developing allergies. Many of the up-regulated genes relating to asthma were from the arginine metabolic pathway. Other genes, such as ADAM8, SPRR2A and SPRR2B were also strongly up-regulated in asthma. Treatment of asthma may be accomplished by administering compositions which decrease the levels of Arginase I, Arginase II, CAT2, or other arginase pathway members in the lung. Additionally, detection of altered levels of these proteins or the mRNA encoding them may be useful to diagnose the presence of asthma in a patient.
    Type: Application
    Filed: April 16, 2007
    Publication date: August 16, 2007
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Marc Rothenberg, Nives Zimmermann
  • Cytokine inhibition of eosinophils
    Publication number: 20050191273
    Abstract: The cytokine CXCL9 (MIG) inhibited eosinophil responses by a CCR3- and Rac2-dependent mechanism.
    Type: Application
    Filed: March 28, 2005
    Publication date: September 1, 2005
    Inventors: Marc Rothenberg, Patricia Fulkerson
  • Eotaxin: an eosinophil chemoattractant
    Patent number: 6780973
    Abstract: Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: August 24, 2004
    Assignees: President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: Andrew D. Luster, Philip Leder, Marc Rothenberg, Eduardo Garcia
  • Nucleic acid encoding eotaxin
    Patent number: 6403782
    Abstract: Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.
    Type: Grant
    Filed: August 4, 1999
    Date of Patent: June 11, 2002
    Assignees: President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: Andrew D. Luster, Philip Leder, Marc Rothenberg, Eduardo Garcia